FDA must publish when drug patents expire—ending secrecy that delays cheaper alternatives

What it does

This bill requires the FDA to publicly disclose when biological drug patents and exclusivity periods expire, and to do so within 30 days of licensure for new drugs or within 2 years for older drugs already on the market. By making these expiration dates transparent and predictable, the bill aims to help generic and biosimilar manufacturers know when they can legally enter the market, reducing delays and uncertainty that currently protect brand-name biologics from competition.

Why we flagged it

The bill's core mechanism is a transparency mandate: requiring the FDA to publish exclusivity expiration dates for biological products on a fixed timeline. This is a procedural reform designed to accelerate generic and biosimilar market entry by eliminating information delays that currently favor brand-name manufacturers.

What the text implies

• Predictable exclusivity expiration dates may accelerate biosimilar development timelines, potentially shortening the effective market exclusivity period for brand-name biologics beyond the statutory term if manufacturers can now plan launches with certainty.
• The 2-year retroactive disclosure requirement for pre-enactment drugs may create a one-time administrative burden on FDA but also a sudden flood of competitive filings once older drug exclusivity dates become public.
• Transparency of exclusivity periods could enable patent litigation strategies by biosimilar makers, who can now plan Paragraph IV challenges with precise knowledge of when they can launch.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens benefit from faster generic and biosimilar competition, which typically lowers drug prices and increases access. The bill removes an information asymmetry that currently favors brand-name manufacturers and delays cheaper alternatives. The only cost is to brand-name biologic makers, whose exclusivity periods become predictable rather than opaque—a shift toward transparency and competition, not a restriction on citizens' rights.

Who stands to gain

• generic and biosimilar manufacturers
• pharmacy benefit managers (via lower acquisition costs)
• health insurers (via lower drug costs)

Named in the bill

FDA, HHS Secretary, Public Health Service Act Section 351, biological products, biosimilar manufacturers, brand-name biologic manufacturers

Where it stands

1 cosponsor: 1 Republicans.

• Apr 16, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Apr 16, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.